title: Another LAP in the race.
abstract: The unique promise of latency-associated peptide resides in its selective presence on regulatory T cells (Treg) in the activated setting after patients are treated with immunomodulators such as anti-CTLA-4. The improved ability to track, scrutinize, and potentially target Tregs in this manipulated environment will be increasingly critical in developing immune-based therapies for patients with cancer.
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington 98109, USA.
authors.forename: Sylvia M
authors.initials: SM
authors.lastname: Lee
authors.forename: Cassian
authors.initials: C
authors.lastname: Yee
mesh_terms: D006801:Humans; D050378:T-Lymphocytes, Regulatory / Q000166:cytology* / Q000276:immunology*